{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:00:21Z","timestamp":1780484421435,"version":"3.54.1"},"reference-count":36,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Obesity and type 2 diabetes mellitus (T2DM) are both modern-day pandemics, significantly impacting worldwide healthcare. The glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide is a novel treatment for both T2DM and obesity; however, it can be associated with an increased risk of venous thromboembolism (VTE).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case presentation:<\/jats:bold>\n                    This case report describes a 59-year-old woman with T2DM who received semaglutide for the management of glycemic levels and also experienced the additional advantage of weight reduction. Within 6 months of initiating GLP1-RA, the patient presented with lower back pain associated with nausea and poor oral intake. She had no known risk factors for VTE or thrombophilia or any history of significant illness in her family. Her physical examination revealed no significant findings; only mild leukocytosis and neutrophilia were detected. She underwent an abdominal computed tomography scan, which revealed intrahepatic portal vein thrombosis without evidence of liver cirrhosis or abdominal malignancy. Her symptoms improved with oral anticoagulation (rivaroxaban). The result of the thrombophilia examination was negative for inherited or acquired thrombophilia, with the exception of mutation of Janus kinase 2, which may increase the risk of thrombosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The use of GLP1-RA is increasing due to the growing desire for weight loss medications; therefore, it is pertinent for physicians to have a better understanding of the possible risks for thrombosis before initiating GLP1-RA treatment.\n                  <\/jats:p>","DOI":"10.5339\/qmj.2025.57","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:30:47Z","timestamp":1752579047000},"source":"Crossref","is-referenced-by-count":1,"title":["Portal vein thrombosis in a patient on semaglutide"],"prefix":"10.5339","volume":"2025","author":[{"given":"Mohammed F.","family":"Farooqi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Tawam Hospital, Al-Ain, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tawam Hospital, Al-Ain, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Arshad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tawam Hospital, Al-Ain, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Agha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates"},{"name":"Department of Diabetes & Endocrinology, Tawam Hospital, Al-Ain, United Arab Emirates*Correspondence: Adnan Agha adnanagha@uaeu.ac.ae"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3277","reference":[{"key":"CIT0001","series-title":"In: StatPearls","article-title":"BMI classification percentile and cut off points","author":"Weir\n \nCB","year":"2023"},{"key":"CIT0002","series-title":"Lancet","first-page":"157\u201363","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Consultation WHOE","year":"(2004)"},{"key":"CIT0003","series-title":"Cell Metab","first-page":"740\u201356","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker\n \nDJ","year":"2018"},{"key":"CIT0004","series-title":"Front Endocrinol (Lausanne)","first-page":"155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen\n \nLB","year":"2019"},{"key":"CIT0005","series-title":"Lancet","first-page":"971\u201384","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies\n \nM","year":"2021"},{"key":"CIT0006","series-title":"J Clin Exp Hepatol","first-page":"965\u201379","article-title":"Portal vein thrombosis in cirrhosis","volume":"12","author":"Shukla\n \nA","year":"2022"},{"issue":"(Suppl. S3)","key":"CIT0007","series-title":"J Gastroenterol Hepatol","first-page":"S224\u20137","article-title":"Spectrum of portal vein thrombosis in the West","volume":"17","author":"Valla\n \nDC","year":"2002"},{"key":"CIT0008","series-title":"J. Hepatol","first-page":"736\u201341","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano\n \nL","year":"2004"},{"key":"CIT0009","series-title":"Gastroenterology","first-page":"1582\u201399","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata\n \nNM","year":"2019"},{"key":"CIT0010","series-title":"Hepatology","first-page":"210\u20138","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier\n \nA","year":"2010"},{"key":"CIT0011","series-title":"A prospective evaluation of primary myeloproliferative disorders","first-page":"1063\u20139","article-title":"Etiology of portal vein thrombosis in adults","volume":"94","author":"Valla\n \nD","year":"1988"},{"key":"CIT0012","series-title":"Indian J Gastroenterol","first-page":"629\u201341","article-title":"Prothrombotic states in portal vein thrombosis and Budd-Chiari syndrome in India: a systematic review and meta-analysis","volume":"42","author":"Giri\n \nS","year":"2023"},{"key":"CIT0013","series-title":"Haematologica","first-page":"70\u201381","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy\n \nA","year":"2019"},{"key":"CIT0014","series-title":"Indian J Hematol Blood Transfus","first-page":"700\u20134","article-title":"JAK2V617F mutation in patient with splanchnic vein thrombosis","volume":"36","author":"Kumar\n \nN","year":"2020"},{"key":"CIT0015","series-title":"J Thromb Thrombolysis","first-page":"388\u201396","article-title":"The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis","volume":"34","author":"Yonal\n \nI","year":"2012"},{"key":"CIT0016","series-title":"Open J Prev Med","first-page":"49","article-title":"The effects of obesity on venous thromboembolism: a review","volume":"2","author":"Yang\n \nG","year":"2012"},{"issue":"(6)","key":"CIT0017","series-title":"Endocr J","first-page":"739\u201342","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin\n \nDG","year":"2021"},{"issue":"(12)","key":"CIT0018","series-title":"Cureus","first-page":"e50051","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel\n \nSL","year":"2023"},{"key":"CIT0001","series-title":"In: StatPearls","article-title":"BMI classification percentile and cut off points","author":"Weir\n \nCB","year":"2023"},{"key":"CIT0002","series-title":"Lancet","first-page":"157\u201363","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Consultation WHOE","year":"(2004)"},{"key":"CIT0003","series-title":"Cell Metab","first-page":"740\u201356","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker\n \nDJ","year":"2018"},{"key":"CIT0004","series-title":"Front Endocrinol (Lausanne)","first-page":"155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen\n \nLB","year":"2019"},{"key":"CIT0005","series-title":"Lancet","first-page":"971\u201384","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies\n \nM","year":"2021"},{"key":"CIT0006","series-title":"J Clin Exp Hepatol","first-page":"965\u201379","article-title":"Portal vein thrombosis in cirrhosis","volume":"12","author":"Shukla\n \nA","year":"2022"},{"issue":"(Suppl. S3)","key":"CIT0007","series-title":"J Gastroenterol Hepatol","first-page":"S224\u20137","article-title":"Spectrum of portal vein thrombosis in the West","volume":"17","author":"Valla\n \nDC","year":"2002"},{"key":"CIT0008","series-title":"J. Hepatol","first-page":"736\u201341","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano\n \nL","year":"2004"},{"key":"CIT0009","series-title":"Gastroenterology","first-page":"1582\u201399","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata\n \nNM","year":"2019"},{"key":"CIT0010","series-title":"Hepatology","first-page":"210\u20138","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier\n \nA","year":"2010"},{"key":"CIT0011","series-title":"A prospective evaluation of primary myeloproliferative disorders","first-page":"1063\u20139","article-title":"Etiology of portal vein thrombosis in adults","volume":"94","author":"Valla\n \nD","year":"1988"},{"key":"CIT0012","series-title":"Indian J Gastroenterol","first-page":"629\u201341","article-title":"Prothrombotic states in portal vein thrombosis and Budd-Chiari syndrome in India: a systematic review and meta-analysis","volume":"42","author":"Giri\n \nS","year":"2023"},{"key":"CIT0013","series-title":"Haematologica","first-page":"70\u201381","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy\n \nA","year":"2019"},{"key":"CIT0014","series-title":"Indian J Hematol Blood Transfus","first-page":"700\u20134","article-title":"JAK2V617F mutation in patient with splanchnic vein thrombosis","volume":"36","author":"Kumar\n \nN","year":"2020"},{"key":"CIT0015","series-title":"J Thromb Thrombolysis","first-page":"388\u201396","article-title":"The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis","volume":"34","author":"Yonal\n \nI","year":"2012"},{"key":"CIT0016","series-title":"Open J Prev Med","first-page":"49","article-title":"The effects of obesity on venous thromboembolism: a review","volume":"2","author":"Yang\n \nG","year":"2012"},{"issue":"(6)","key":"CIT0017","series-title":"Endocr J","first-page":"739\u201342","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin\n \nDG","year":"2021"},{"issue":"(12)","key":"CIT0018","series-title":"Cureus","first-page":"e50051","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel\n \nSL","year":"2023"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2025\/2\/article-57.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2025\/2\/article-57.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2025\/2\/article-57.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:17:19Z","timestamp":1777310239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2025\/2\/article-57.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":36,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2025.57","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}